LY3502970 is an investigational medication being studied for its potential to help reduce body weight in adults who are either obese or overweight and have related health conditions. The trial aims to determine if this medication is more effective than a placebo in achieving weight loss. Participants take this medication orally once a day.

Obesity – A condition characterized by excessive body fat accumulation that may impair health. It develops when calorie intake consistently exceeds calorie expenditure, leading to weight gain. Over time, this can result in increased fat storage, particularly around the abdomen. Obesity is often associated with a sedentary lifestyle and poor dietary habits. It can lead to various health issues, including joint problems and metabolic disorders. The progression of obesity can vary, with some individuals gaining weight rapidly, while others may experience a more gradual increase.

Overweight – A condition where an individual has more body weight than is considered healthy for their height. It occurs when there is an imbalance between calories consumed and calories burned. Over time, this can lead to an increase in body fat, although not as excessive as in obesity. Being overweight can be a precursor to obesity if lifestyle changes are not made. It is often linked to a lack of physical activity and unhealthy eating patterns. The progression can be slow or fast, depending on various factors, including genetics and lifestyle choices.

Overweight or Obesity – This term encompasses both conditions where there is an excess of body weight or fat. It involves a spectrum ranging from slightly above normal weight to significantly high levels of body fat. The progression from overweight to obesity can occur if weight gain continues unchecked. Both conditions are influenced by similar factors, such as diet, physical activity, and genetics. They can lead to similar health complications if not addressed. The transition between these states can vary widely among individuals.